Aptorum Group Ltd Class A (APM) is a Healthcare · Biotechnology company listed on NASDAQ. Price $5.26 (+10.27%), Market cap $0.01B, 52-week low–high $0.74 ~ $4.25.
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa. The company also develops SACT-COV19, a repurposed small molecule which is in preclinical trial for the treatment of coronavirus
Financial statements, price targets, institutional (13F) holdings and related news for Aptorum Group Ltd Class A are updated in real time on BlackAll Trade.
Aptorum Group Ltd Class A trades at $5.26 (+10.27%). Real-time quotes and charts are available on BlackAll Trade.
Aptorum Group Ltd Class A has a market cap of about $0.01B.
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and